Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives

(2017) Ken-ichi Matsuoka   INTERNATIONAL JOURNAL OF HEMATOLOGY

Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance

(2016) Lei Gu et al.   Molecular Medicine Reports

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions

(2016) Alejandro Villarino et al.   eLife

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

(2015) Caroline von Spee-Mayer et al.   ANNALS OF THE RHEUMATIC DISEASES

Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE

(2015) Jens Y Humrich et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment

(2015) Agneta Zickert et al.   BMC IMMUNOLOGY

Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity

(2015) Roba M. Talaat et al.   CYTOKINE

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

(2015) Aixin Yu et al.   DIABETES

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

FOXP3+ Treg Cells and Gender Bias in Autoimmune Diseases

(2015) Jia Nie et al.   Frontiers in Immunology

Th17 and regulatory T cell balance in autoimmune and inflammatory diseases

(2014) Mélissa Noack et al.   AUTOIMMUNITY REVIEWS

The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function

(2014) Andrew N. Macintyre et al.   Cell Metabolism

The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiationin vitroandin vivoin kidney transplant recipients

(2014) Kyoung Woon Kim et al.   IMMUNOLOGY

Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells

(2014) Leontina M. Banica et al.   International Journal of Rheumatic Diseases

Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin

(2014) Samik Basu et al.   JOURNAL OF IMMUNOLOGY

Akt-Dependent Enhanced Migratory Capacity of Th17 Cells from Children with Lupus Nephritis

(2014) Sudhir Kshirsagar et al.   JOURNAL OF IMMUNOLOGY

Simultaneous dissection and comparison of IL-2 and IL-15 signaling pathways by global quantitative phosphoproteomics

(2014) Nerea Osinalde et al.   PROTEOMICS

Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand

(2014) D Nazzal et al.   Cell Death & Disease

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

(2014) Emeline Castela et al.   JAMA Dermatology

The Pathology of T Cells in Systemic Lupus Erythematosus

(2014) Anselm Mak et al.   Journal of Immunology Research

Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity

(2013) Kevin Goudy et al.   CLINICAL IMMUNOLOGY

IL-2R Signaling Is Essential for Functional Maturation of Regulatory T Cells during Thymic Development

(2013) G. Cheng et al.   JOURNAL OF IMMUNOLOGY

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

(2013) K.-i. Matsuoka et al.   Science Translational Medicine

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

PI3K-Akt-mTORC1-S6K1/2 Axis Controls Th17 Differentiation by Regulating Gfi1 Expression and Nuclear Translocation of RORγ

(2012) Yutaka Kurebayashi et al.   Cell Reports

Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus

(2011) Sebastian Dolff et al.   CLINICAL IMMUNOLOGY

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis

(2011) Qian Xing et al.   RHEUMATOLOGY INTERNATIONAL

Th17 and natural Treg cell population dynamics in systemic lupus erythematosus

(2009) Ji Yang et al.   ARTHRITIS AND RHEUMATISM

Effects of rituximab on resistant SLE disease including lung involvement

(2008) JA Reynolds et al.   LUPUS

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus

(2007) A Podolskaya et al.   ARCHIVES OF DISEASE IN CHILDHOOD